Board of Directors
Peter Suzdak, Ph.D., President & CEO
James Barrett, Ph.D.
Dr. Barrett joined NEA in 2001 as a General Partner. He specializes in biotechnology and
works with members of NEA's healthcare investment group on medical devices, healthcare
information systems and healthcare services companies. Present board memberships include
CoGenesys, GlycoMimetics, Inhibitex, Inc. (NASDAQ: INHX), Iomai Corporation, Nucleonics,
Inc., Peptimmune, Inc., Pharmion Corporation (NASDAQ: PHRM), Ruxton Pharmaceuticals,
Inc., Sensors for Medicine and Science, Supernus Pharmaceuticals, and Targacept. He also
serves on the board of MedImmune. Prior to NEA, Dr. Barrett served as
Founder/Chairman/CEO of Sensors for Medicine and Science (1997 - 2001) where he
remains Chairman. Prior to that, he was Chairman/CEO of Genetic Therapy (1987 - 1995),
President/CEO of Life Technologies (1985 - 1987), and President/CEO of Bethesda Research
Labs (1982 - 1983). Prior to 1982, Dr. Barrett worked in various divisions of SmithKline. NEA
and Dr. Barrett have worked together since 1982 when he was recruited to run Bethesda
Research Laboratories, which merged with Life Technologies. NEA then backed Dr. Barrett at
Genetic Therapy and later at Sensors for Medicine and Science. Dr. Barrett received a PhD
in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara,
and a BS in Chemistry from Boston College.
Robert Garland, M.D.
Dr. Garland is a Partner at NEA; he joined NEA in 2003 and invests in biopharmaceuticals
and medical devices. Prior to NEA, in addition to clinical practice, he was with McKinsey &
Company's Pharmaceutical & Medical Products and Corporate Finance & Strategy
practices. At McKinsey, Dr. Garland worked with biotech, pharmaceutical, medical device,
diagnostics, and private equity clients to evaluate investments, formulate product and
corporate strategies and build businesses. Dr. Garland completed his residency and
fellowship training at the University of California, San Francisco. He received MBA and MPH
degrees from the University of California, Berkeley, his MD from Baylor College of Medicine,
and his BSEE from Rice University.
Chris Kroeger, M.D.
Dr. Kroeger joined Aurora in 2003 and became a Principal in 2005. Dr. Kroeger focuses on
biopharmaceutical and medical device opportunities and brings a broad spectrum of
business, clinical and scientific expertise to Aurora’s investments in these sectors. Dr. Kroeger
led or co-led syndicated investments in Cardioxyl Pharmaceuticals, Hyberbranch Medical,
and Neotropix, and led Aurora’s investments in Cardiofocus and Paringenix. Prior to joining
Aurora, Chris trained in general surgery at Brigham and Women’s Hospital/Harvard Medical
School where he was involved in the medical and surgical care of transplant, trauma,
vascular, cardiac and general surgical patients. He has over seven years of clinical
experience in both academic and community hospital practices, and is a licensed physician
in North Carolina. Dr. Kroeger also has significant basic science research experience
primarily in signal transduction, including work on the molecular biology and genetics of
apoptosis, and the transcriptional regulation of Interleukin-2 in human T-cells. Dr. Kroeger
previously worked with Arthur D. Little/Decision Resources, providing industry and technology
analysis to biotechnology and pharmaceutical companies. Additionally, while attending
business school, Chris worked in Corporate Development at Genzyme. Dr. Kroeger received a
B.A. in Biology from Harvard University, his M.D. from Stanford University School of Medicine
and an MBA from Harvard Business School. Dr. Kroeger serves on the boards of Cardiofocus,
Hyperbranch Medical Technologies, Neotropix and ParinGenix, and serves as an observer on
the boards of Aldagen, Argos, Metastatix and Regado. Chris also serves on the Johns Hopkins
Technology Alliance.
Peter Suzdak, Ph.D., President & CEO
James Barrett, Ph.D.
Dr. Barrett joined NEA in 2001 as a General Partner. He specializes in biotechnology and
works with members of NEA's healthcare investment group on medical devices, healthcare
information systems and healthcare services companies. Present board memberships include
CoGenesys, GlycoMimetics, Inhibitex, Inc. (NASDAQ: INHX), Iomai Corporation, Nucleonics,
Inc., Peptimmune, Inc., Pharmion Corporation (NASDAQ: PHRM), Ruxton Pharmaceuticals,
Inc., Sensors for Medicine and Science, Supernus Pharmaceuticals, and Targacept. He also
serves on the board of MedImmune. Prior to NEA, Dr. Barrett served as
Founder/Chairman/CEO of Sensors for Medicine and Science (1997 - 2001) where he
remains Chairman. Prior to that, he was Chairman/CEO of Genetic Therapy (1987 - 1995),
President/CEO of Life Technologies (1985 - 1987), and President/CEO of Bethesda Research
Labs (1982 - 1983). Prior to 1982, Dr. Barrett worked in various divisions of SmithKline. NEA
and Dr. Barrett have worked together since 1982 when he was recruited to run Bethesda
Research Laboratories, which merged with Life Technologies. NEA then backed Dr. Barrett at
Genetic Therapy and later at Sensors for Medicine and Science. Dr. Barrett received a PhD
in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara,
and a BS in Chemistry from Boston College.
Robert Garland, M.D.
Dr. Garland is a Partner at NEA; he joined NEA in 2003 and invests in biopharmaceuticals
and medical devices. Prior to NEA, in addition to clinical practice, he was with McKinsey &
Company's Pharmaceutical & Medical Products and Corporate Finance & Strategy
practices. At McKinsey, Dr. Garland worked with biotech, pharmaceutical, medical device,
diagnostics, and private equity clients to evaluate investments, formulate product and
corporate strategies and build businesses. Dr. Garland completed his residency and
fellowship training at the University of California, San Francisco. He received MBA and MPH
degrees from the University of California, Berkeley, his MD from Baylor College of Medicine,
and his BSEE from Rice University.
Chris Kroeger, M.D.
Dr. Kroeger joined Aurora in 2003 and became a Principal in 2005. Dr. Kroeger focuses on
biopharmaceutical and medical device opportunities and brings a broad spectrum of
business, clinical and scientific expertise to Aurora’s investments in these sectors. Dr. Kroeger
led or co-led syndicated investments in Cardioxyl Pharmaceuticals, Hyberbranch Medical,
and Neotropix, and led Aurora’s investments in Cardiofocus and Paringenix. Prior to joining
Aurora, Chris trained in general surgery at Brigham and Women’s Hospital/Harvard Medical
School where he was involved in the medical and surgical care of transplant, trauma,
vascular, cardiac and general surgical patients. He has over seven years of clinical
experience in both academic and community hospital practices, and is a licensed physician
in North Carolina. Dr. Kroeger also has significant basic science research experience
primarily in signal transduction, including work on the molecular biology and genetics of
apoptosis, and the transcriptional regulation of Interleukin-2 in human T-cells. Dr. Kroeger
previously worked with Arthur D. Little/Decision Resources, providing industry and technology
analysis to biotechnology and pharmaceutical companies. Additionally, while attending
business school, Chris worked in Corporate Development at Genzyme. Dr. Kroeger received a
B.A. in Biology from Harvard University, his M.D. from Stanford University School of Medicine
and an MBA from Harvard Business School. Dr. Kroeger serves on the boards of Cardiofocus,
Hyperbranch Medical Technologies, Neotropix and ParinGenix, and serves as an observer on
the boards of Aldagen, Argos, Metastatix and Regado. Chris also serves on the Johns Hopkins
Technology Alliance.
 |
| |
 |
| |
 |
| |
 |
| |
 |
 | |  | |  | |  |
| Copyright 2007 Cardioxyl Pharmaceuticals, Inc. All rights reserved. |